MetaVia Reports Strong Phase 1 DA-1726 Weight Loss Data and Synergistic Preclinical Vanoglipel Results
MTVA has more than doubled off its 52-week low of $0.966 on elevated volume (4.4× avg).
Summary
MetaVia announced new positive Phase 1 data for its obesity drug DA-1726, showing up to 9.1% weight reduction, and preclinical data for vanoglipel demonstrating synergistic effects in MASH and Type 2 Diabetes.
Key Events · Product Development and Regulatory · MTVA
-
DA-1726 Phase 1 Data
Reported up to 9.1% mean body weight reduction at Day 54 in obese adults, with good tolerability and no evidence of plateau, supporting continued development for obesity.
-
Vanoglipel for MASH
Preclinical data showed synergistic hepatoprotective and weight-loss effects when combined with resmetirom, including a 23.6% body weight reduction in a mouse model.
-
Vanoglipel for Type 2 Diabetes
Preclinical study demonstrated enhanced glycemic control and 16.3% body weight reduction when combined with metformin in a mouse model.
-
Strategic Pipeline Advancement
These results reinforce the differentiated potential of MetaVia's cardiometabolic pipeline, crucial for a company with a recent going concern warning and upcoming reverse stock split vote.
Analysis · MTVA · Life Sciences
This 8-K details highly positive clinical and preclinical data for MetaVia's lead drug candidates, DA-1726 and vanoglipel. The 9.1% body weight reduction for DA-1726 in Phase 1 is a significant outcome for an obesity drug, especially with good tolerability and no plateau, reinforcing its competitive potential. The synergistic effects of vanoglipel in combination therapies for MASH and Type 2 Diabetes also broaden its market opportunity. For a micro-cap company facing a going concern warning, these strong clinical advancements are critical for attracting investment, securing partnerships, and extending its operational runway.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MTVA was trading at $2.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3M. The 52-week trading range was $0.97 to $19.03. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.